Elevating future therapies to a new level: Greenovation transformed into Eleva. Join us at www.elevabiologics.com

First Preclinical Data Show Full Bioactivity of Greenovation’s Moss-FH

Publication in the Journal of the American Society of Nephrology

FREIBURG, Germany, December 15, 2016

Scientists of Greenovation Biotech GmbH and the Universities of Freiburg and Jena have published data in the Journal of the American Society of Nephrology showing full bioactivity of the human complement factor H produced in the moss Physcomitrella patens (moss-FH). The results demonstrate its ability to control complement activation in serum derived from aHUS patients as well as in a C3G mouse model.

Genetic defects in complement regulatory proteins can lead to severe diseases, including atypical haemolytic uremic syndrome (aHUS), C3 glomerulopathies (C3G) and age-related macular degeneration (AMD). Most of the mutations found in patients with these diseases affect the glycoprotein complement factor H, one of the main regulators of the alternative pathway of complement activation.

Replacement therapy with recombinantly produced Factor H is a promising option. But Factor H is a complex and difficult-to-express glycoprotein which is not yet available for clinical use. Novel treatments in general, specifically those targeting alternative pathway activation and regulation, are highly desirable. Substitution with biologically active factor H could potentially treat a variety of diseases that involve increased alternative pathway activation.

The published results suggest moss-FH might offer a safe treatment option for the therapeutic control of complement activation.

"This encouraging data reinforces our belief that moss-FH has the potential to become a treatment option for kidney diseases, especially aHUS,” says Dr. Thomas Frischmuth, CEO of Greenovation, “we are excited to see more results coming out of this promising cooperation.”

Cooperation partners are the Department of Pediatrics and Adolescent Medicine, University of Freiburg Medical Center, the Chair Plant Biotechnology, University of Freiburg, Greenovation Biotech GmbH, and the Leibniz Institute for Natural Product Research and Infection Biology, Friedrich Schiller University, Jena.

The results mentioned in this press release were published in:
Michelfelder, S., J. Parsons, L.L. Bohlender, S.N.W. Hoernstein, H. Niederkrüger, A. Busch, N. Krieghoff, J. Koch, B. Fode, A. Schaaf, T. Frischmuth, M. Pohl, P.F. Zipfel, R. Reski, E.L. Decker, K. Häffner (2016): Moss-produced, glycosylation-optimized human factor H for therapeutic application in complement disorders. Journal of the American Society of Nephrology 28, doi: 10.1681/ASN.2015070745.

The full article is available under http://jasn.asnjournals.org/content/early/2016/12/07/ASN.2015070745.abstract

About Greenovation Biotech GmbH

Greenovation develops next-generation therapeutics using its proprietary BryoTechnology platform. The company aims to optimize the production of highly-efficient glycoproteins for proprietary and customer use.

Greenovation is a privately owned biopharmaceutical company based in Heilbronn, Germany. It was founded in 1999 by Prof. Dr. Ralf Reski and Prof. Dr. Gunter Neuhaus. Today, Greenovation Biotech GmbH is majority-owned by Zukunftsfonds Heilbronn and L-EigenkapitalAgentur (Karlsruhe).

Contact and further information

Greenovation Biotech GmbH
p. +49 761 470 99 0
e-mail: bd@greenovation.com
web: www.greenovation.com